Syndax Pharmaceuticals, Inc. (1T3.F)
| Previous close | 19.90 |
| Open | 19.80 |
| Bid | 19.90 x 80000 |
| Ask | 20.00 x 80000 |
| Day's range | 19.80 - 19.80 |
| 52-week range | 10.40 - 22.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.706B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.
- PR Newswire
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended March 31, 2024, and provided a business update.
- PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on May 1, 2024 the Company granted inducement awards to purchase up to 100,600 shares of common stock to six new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying
